I suspect the successful trial for the Merck/Moderna cancer

New Post Public Reply Private Reply Replies (3) Message Board
sherlock57
1,087
I suspect the successful trial for the Merck/Moderna cancer vaccine will probably be the final nail in the coffin for those hoping Merck will come in and buy out Cytodyn. Merck has been doing quite a bit to prepare for the famous “patent cliff” that it faces in 2028. Let’s take a quick look at what they’ve added recently—including other therapeutic areas like infectious diseases and immunology, as well as oncology—to see why they would pass on Cytodyn.

First, though, a huge multi-national Big Pharma like Merck can’t just pick up a new drug and run with it… just because outsiders like us think/know it will work exceptionally well. They have a great deal of institutional momentum—as well as billions of dollars—invested in their pipeline. Think about the egos in the C-suite, and the reputations/jobs on the line for those executives who argue for or against a particular acquisition. Every acquisition or licensing deal has it’s own contingent of supporters behind it, all invested in the choices they argued and fought for. There are something like 1800 clinical trials going on with Keytruda right now (according to Merck). Just in oncology, that is a great deal of freight moving forward, already budgeted and accounted for. And executives in corporations tend to get in line when consensus is achieved; they tend to close ranks and move forward with conviction. That can lead to group-think, with expectations already banked before trials are done. What are the hot oncology drugs these days? Bi-specifics! ADCs! Not CCR5-inhibitors… Even if Merck expressed interest, where would we fit in their developmental timeline? And what would the Bio/Pharma press say if Merck did a deal with a sketchy outfit like Cytodyn, when other CCR5 inhibitors didn’t do shit in earlier trials?

The big tell for me was they didn’t pursue Revolution Medicines a short while back, even though they have an exceptional cancer drug. They didn’t want to overpay, apparently. Why would they bother with a small biotech like Cytodyn, with hardly any data in cancer, even though the data available is pretty great…

Merck has huge hopes for sac-TMT, acquired in 2022 from Kelun Biotech for $1.4 billion, as they aced a Phase 3 trial in endometrial cancer recently (at an interim look, no less). They have 17 global Phase 3 trials planned for the drug in the next few years (!) financed by a 700 million dollar funding agreement with Blackstone Life Sciences (Blackstone gets a low-to-mid single-digit royalties for their 700 million). And Merck built upon the Kelun agreement with a separate 9.3 billion dollar pact for 7 additional ADCs. Talk about institutional freight and weight and momentum! NSCLC is the first big indication there…

In Small Cell Lung Cancer Merck has MK-6070 from Harpoon Therapeutics, bought for $680 million in 2024, moving into Phase 3 studies. In Myleoproliferative Neoplasms they have Bomedemstat from Imago BioSciences, bought for $1.35 billion in 2023, in a Phase 2b/3 trial. And this year they bought Terns Pharmaceuticals for $6.7 billion, a Phase 2 drug with a Breakthrough Designation for CML. That is $19.38 billion in oncology investments alone (including bio-bucks based on milestones achieved, just to be clear).

Add to these oncology assets an approved COPD drug (ensifentrine) they acquired when they bought Verona Pharma ($10 billion/2025). Same goes for Winrevair for pulmonary arterial hypertension ($11.5 billion/2021). And MK-7240, from Prometheus Biosciences, just passed a Phase 3 trial in UC and Crohn’s disease ($10.8 billion). Last but not least, the Cidara acquisition gave them a Phase 3-ready antiviral for influenza prophylaxis (CD288) as well as a preclinical CCR5 inhibitor in preclinical studies ($9.2 billion/2026). They expect CD388 and Winrevair to be blockbusters. Along with sac-TMT of course. So Merck has spent $60 billion in combined oncology and non-oncology acquisitions… In the last 5 years! Gotta expect a few blockbusters for that kind of money I guess.

The above doesn’t even include the approval of Keytruda Qlex, which covers a significant amount of the expected patent cliff losses. I’d say Merck has done pretty well for themselves, all told. Without Leronlimab in the mix!

But there are a couple avenues that might make sense for Merck to get in the act and make a play for leronlimab. The first is that Merck doesn’t have much in the way of colorectal cancer assets. With great results for leronlimab in mCRC, Merck could conceivably spend a few billion in bio-bucks to license (or more to buy) a Phase 3-ready asset they would put to work rather quickly as part of a new SOC. And then, they could develop the ICI/leronlimab combo at their leisure… Or develop it more aggressively if they thought it would fit into their Big Picture plans.

One of Merck’s marketing executives might get all hot and bothered about the revolutionary possibilities that two effective cancer therapeutics, delivered subcutaneously, might have on the cancer treatment paradigm. That would be a far-thinking executive… but he or she might be out there. And they could easily be at BMS, or Roche… because, along with Merck, all three have a subcutaneous ICI. In fact, apparently Hoffman recently said they have a commitment from some un-named Big Pharma to provide an ICI for the proposed TNBC trial. If it turns out to be BMS, or Roche, or Merck, and they use a sub-q ICI in Cytodyn’s trial, and position themselves as “the future” of cancer care via a subcutaneous cure and/or long-term cancer management… well, that would be very significant. It would demonstrate to me that whatever company it is, they are serious about taking full advantage of Leronlimab’s strengths, and share a vision for patient-friendly cancer therapeutics. In other words, they would be all-in with Leronlimab and an ICI as the sub-q future… and they would market it that way, and wouldn’t be tempted to slow-walk development to preserve existing capital commitments. It would be an important tell that would make me take that company very seriously as a partner or owner… even if it was Merck, finally coming to their senses.

Hey, even if Merck doesn’t pull the trigger, I hope they are in the boardroom as negotiations progress. They would probably read the room and bid up the price, just to stick it to BMS or Roche or whoever… even if they didn’t really want the asset. I’d be okay with that!

By the way, I’m not really sold on the personalized Merck/Moderna cancer vaccine. Too expensive, works only to prevent recurrence after surgery… I mean, it's great for high-risk melanoma patients... But I think it will take a great deal of additional extensive development... Because Leronlimab (with or without an ICI or chemo?) does essentially what the cancer vaccine does—mobilize the immune system to search and destroy. And it takes down the defensive stroma tumors shield themselves with. And it revitalizes the immune system to prevent remission/recurrence. And it is off the shelf. I’ll write more about this some other time.
For now, I'll say good bye, Merck. I wish I could say it's been real...

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 121

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading

Top 5 Most Recently Viewed Articles

Hydreight Technologies Inc. Holds Successful Annual Meeting

Updated Category News Views 147

Successful Results from Hydreight Technologies Inc.'s Annual Meeting Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) proudly shares the positive outcomes from their recent Annual General Meeting. Conducted virtually, the meeting brought together shareholders who actively participated in decision-making. Shareholder Voting Outcomes During this significant...

Continue Reading
Discovering Leadership Themes in Anusia Gillespie's Novel

Updated Category News Views 146

Anusia Gillespie's Soul Toll: A Unique Literary Journey Soul Toll is gaining significant recognition for its imaginative storytelling which straddles the realms of ambition and awakening. This debut novel by Anusia Gillespie is becoming a staple not just in libraries, but also in yoga studios and leadership circles. Recognition from Kirkus Reviews The November issue of...

Continue Reading
First-Time Buyers' Guide to Stillwater's Housing Market

Updated Category News Views 64

The Challenge of Buying a Home in Stillwater Walking into Stillwater's housing market as a first-time buyer is like stepping onto a high-wire act. You're balancing dreams with dollars, all while the ground beneath you keeps shifting. What stands out from HelloNation's deep dive into this market, featuring Page Provence of Fisher Provence Realtors Inc., is that knowledge...

Continue Reading
Celebrating Excellence: National Catholic Reporter's 70 Awards

Updated Category News Views 127

Outstanding Achievement in Catholic Journalism The National Catholic Reporter (NCR) and its affiliated platforms, such as Global Sisters Report (GSR) and EarthBeat, have recently achieved remarkable recognition in the realm of Catholic media. With over 70 awards at the prestigious Catholic Media Awards, NCR has reaffirmed its dedication to delivering independent...

Continue Reading
Centessa Pharmaceuticals Prepares for Major Investor Events

Updated Category News Views 50

Centessa Pharmaceuticals' Upcoming Investor Conferences Centessa Pharmaceuticals plc (Nasdaq: CNTA), a pioneering clinical-stage pharmaceutical company, is set to mark its presence in several prominent investor conferences. The company's mission is to discover and develop transformative medicines aimed at enhancing patient outcomes. Guggenheim Healthcare Innovation...

Continue Reading